General | 03 November 2024
Petroleum Secretary lays foundation stone of Advance Training Institute at ONGC, Goa
The facilities shall also be utilised during India Energy Week 2026
The facilities shall also be utilised during India Energy Week 2026
The new tagline is 'Engineered to Outrun'
The Group sales showed overall improved momentum in Q3 with Syngenta Group China delivering double digit sales growth
The company achieved US$ 11.3 billion of cumulative structural cost savings versus 2019
Social implementation of biomass materials will help to build a bio-based, circular society
DuPont and Zhen Ding will work to enhance end-user applications, advance cutting-edge research and development, improve material performance
The company's third quarter volumes benefited from high cracker operating rates that captured improved margins on merchant ethylene sales
EBITDA before special items increased compared with Q3 2023 due to considerably higher earnings of core businesses
The company has unveiled its new brand, a milestone in its ongoing transformation under the Positive Motion strategy
Consolidated income reached Rs. 696 crore, a 16% increase compared to the second quarter last year, reflecting seventh consecutive quarter of sales growth
EBIT increased primarily due to higher sales volume/mix, higher spreads in chemical intermediates, and improved asset utilization
Operating profit $2.1 billion, adjusted operating profit $2.5 billion, up 7%
PBT for Q2 grows by over 156% over Q1
Gross profit margin improved by 421 basis points (bps) YoY to 42.6%, driven by several factors such as focus on high-margin new products, normalization of export markets and effective cost management
Robust performance with high volume growth in Q2 FY25 in agrochemical
The Indian construction chemicals market was valued at US$ 3.76 Billion in 2024
The company's performance going forward will be supported by planned expansion initiatives around Vacuum Salt and Bromine, which will start contributing from next year onwards
Aquapharm Chemicals reported a steady performance during the quarter. Q2 FY25 revenue stood at Rs. 362 crore and EBITDA stood at Rs. 50 crore
Astec LifeSciences topline and profitability was severely impacted due lower realizations in key enterprise products
Revenue for Q2FY25 at Rs. 635 crores; for H1FY25 at Rs. 1,202 crores
Subscribe to our newsletter & stay updated.
